Align Technology Inc ALGN

Align Technology, Inc. es una empresa global de dispositivos médicos. La compañía se dedica al diseño, fabricación y comercialización de alineadores transparentes Invisalign, escáneres intraorales iTero y servicios para odontología, así como software de diseño asistido por computadora y fabricación asistida por computadora (CAD/CAM) exocad para laboratorios dentales y profesionales de la odontología. Opera a través de dos segmentos: Alineadores Transparentes y Sistemas y Servicios. Su segmento de Alineadores Transparentes consta de Productos Complejos, que incluyen Invisalign Comprehensive e Invisalign First; Productos No Complejos, que incluyen paquetes Invisalign Moderate, Lite y Express, Invisalign Go e Invisalign Go Plus, y productos No-Caso, que incluyen productos de retención, entrenamiento Invisalign, herramientas de ajuste utilizadas por profesionales dentales durante el tratamiento y productos para consumidores que son complementarios a sus productos principales recetados por médicos. Su segmento de Sistemas y Servicios consiste en sus sistemas de escaneo intraoral iTero.

• Zacks Investment Research 2 oct

  Will Align Technology (ALGN) Beat Estimates Again in Its Next Earnings Report?

  Align Technology, maker of the Invisalign tooth-straightening system, is positioned to potentially beat earnings estimates in its upcoming October 28, 2026 report. The company has a strong track record of beating estimates with an average surprise of 8.64% over the past two quarters. With a positive Earnings ESP of +1.23% combined with a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.

  

• Zacks Investment Research 2 oct

  These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time.

  

• Zacks Investment Research 8 sept

  XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

  DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%, but three dental segments declined, with tariff pressures and lower volumes constraining operating margins. Free cash flow improved to $55M from $16M year-ago.

  

• Zacks Investment Research 8 sept

  Is Cardinal Health Building a New Tech-Enabled Healthcare Platform?

  Cardinal Health is leveraging technology investments across distribution, specialty services, and logistics to operate as a tech-enabled healthcare platform. The company integrated Sonexus into its Nuclear business web-ordering platform for end-to-end digital workflows, achieved a 99% fill rate, and plans $700 million in fiscal 2027 capital spending. Peers CONMED and Align Technology are similarly expanding their technology-driven healthcare solutions.

  

• Zacks Investment Research 2 sept

  Here's How CVS' Improving Balance Sheet Supports Deleveraging

  CVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and Cardinal Health also demonstrate strong liquidity positions with active capital deployment strategies.